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Abstract
Background
Cardio-metabolic risk factors are of increasing concern in HIV-infected individuals, particularly
with the advent of antiretroviral therapy (ART) and the subsequent rise in longevity. However,
the prevalence of cardio-metabolic abnormalities in this population and the differential contri-
bution, if any, of HIV specific factors to their distribution, are poorly understood. Therefore, we
conducted a systematic review and meta-analysis to estimate the global prevalence of meta-
bolic syndrome (MS) in HIV-infected populations, its variation by the different diagnostic crite-
ria, severity of HIV infection, ART used and other major predictive characteristics.
Methods
We performed a comprehensive search on major databases for original research articles
published between 1998 and 2015. The pooled overall prevalence as well as by specific
groups and subgroups were computed using random effects models.
Results
A total of 65 studies across five continents comprising 55094 HIV-infected participants aged
17–73 years (median age 41 years) were included in the final meta-analysis. The overall prev-
alence of MS according to the following criteria were: ATPIII-2001:16.7% (95%CI: 14.6–
18.8), IDF-2005: 18% (95%CI: 14.0–22.4), ATPIII-2004-2005: 24.6% (95%CI: 20.6–28.8),
Modified ATPIII-2005: 27.9% (95%CI: 6.7–56.5), JIS-2009: 29.6% (95%CI: 22.9–36.8), and
EGIR: 31.3% (95%CI: 26.8–36.0). By someMS criteria, the prevalence was significantly
higher in women than in men (IDF-2005: 23.2% vs. 13.4, p = 0.030), in ART compared to
non-ART users (ATPIII-2001: 18.4% vs. 11.8%, p = 0.001), and varied significantly by partici-
pant age, duration of HIV diagnosis, severity of infection, non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs) use and date of study publication. Across criteria, there were
significant differences in MS prevalence by sub-groups such as in men, the Americas, older
publications, regional studies, younger adults, smokers, ART-naïve participants, NNRTIs
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users, participants with shorter duration of diagnosed infection and across the spectrum of
HIV severity. Substantial heterogeneities across and within criteria were not fully explained by
major study characteristics, while evidence of publication bias was marginal.
Conclusions
The similar range of MS prevalence in the HIV-infected and general populations highlights
the common drivers of this condition. Thus, cardio-metabolic assessments need to be rou-
tinely included in the holistic management of the HIV-infected individual. Management strat-
egies recommended for MS in the general population will likely provide similar benefits in
the HIV-infected.
Introduction
The Global Burden of Disease Expert Group estimated that approximately 30 million people
were infected with HIV worldwide in 2013, the majority of whom reside in sub-Saharan Africa
[1]. Life expectancy and quality of life in those infected with HIV have improved dramatically
with the introduction of effective antiretroviral therapy (ART). Between 1990 and 2013, ART
saved an estimated 19.1 million life-years in HIV-infected adults [1].
With increased longevity in HIV-infected individuals other diseases are likely to develop,
similar to the general population. These include obesity, type 2 diabetes mellitus (T2DM) and
other cardio-metabolic diseases. Although exposure to risky behaviours of unhealthy diets and
reduced physical activity levels contribute to these conditions [2], additional influences unique
to HIV-infected populations further increase their susceptibility to cardio-metabolic abnormal-
ities. For example, the use of ART is associated with body fat redistribution and cardio-meta-
bolic abnormalities such as hypertension, dyslipidaemia, insulin resistance, and dysglycaemia
[3]. Moreover, HIV infection itself through chronic inflammation and immune dysfunction
mechanisms is assumed to be an important determinant of dyslipidaemia, atherosclerosis and
T2DM [4].
Cardio-metabolic abnormalities frequently cluster and manifest as the metabolic syndrome
(MS), a constellation of interrelated metabolic disorders comprising abdominal obesity, raised
blood pressure, dyslipidaemia and hyperglycaemia. The importance of the MS is that it is a
powerful predictor of future cardiovascular disease and T2DM [5]. Therefore, determining the
magnitude of MS in a given population highlights the need for preventive and management
strategies, and enables healthcare services planning.
This is particularly relevant in HIV-infected populations who have the potential to develop
cardio-metabolic abnormalities and MS through multiple pathways. Notably, the prevalence of
MS in HIV-infected populations and the differential contributions, if any, of HIV specific
influences on the estimates have yet to be fully examined. Accordingly, we conducted a system-
atic review and meta-analysis to assess the MS prevalence and its relationship with HIV specific
characteristics in the global HIV-infected population.
Methods
Identification of relevant studies
We undertook a comprehensive electronic search across major databases including Medline,
CINAHL, Academic Search Premier, Africa-Wide Information and Scopus to identify relevant
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studies. The search terms comprised combinations of MESH terms, CINAHL headings, and
free words relating to prevalence, metabolic syndrome, and HIV/AIDS (S1 Table). Addition-
ally, we traced the citations of identified articles via the ISI Web of Knowledge, and scanned
the reference lists of review papers and conference proceedings. We also examined publications
on the websites of key organisations such as UNAIDS, WHO, and International AIDS Society.
We limited the search to studies reported from January 1998 to April 2015 because highly
active antiretroviral therapy (HAART) was introduced only in 1996 [6] and the first MS criteria
were defined in 1998 [7]. The last search data was 30th April 2015.
Selection of included studies
Two investigators (KAN and NP) independently reviewed the studies by title, abstract and full
text where relevant for inclusion. Disagreements were resolved by consensus or by consulting a
third investigator (APK). Included studies had to: 1) be population- or hospital-based cross-
sectional studies, 2) comprise adults diagnosed with HIV-infection, treated or not; 3) report
the prevalence of MS overall and by different subgroups of interest, according to any of the
internationally accepted diagnostic criteria for MS (S3 Table); or provide enough data to esti-
mate this prevalence; and 4) be published in English or French. We made no restriction by
sample size, sampling methods or study setting. For studies reported more than once, the arti-
cle with the largest number of participants was used. If an article reported multiple surveys
conducted in different countries, each survey was counted as a separate study (Fig 1).
Assessment of the methodological quality of included studies
We evaluated the methodological quality of the included studies using a checklist adapted from
Hoy et al. [8]. It consists of nine questions that assesses the representativeness of the sample,
the sampling technique, the response rate, the data collection method, the measurement tools,
the case definitions, and the statistical reporting. Each checked question was scored either as
“1” or “0” corresponding respectively to “low risk of bias” and “high risk of bias”. The total
score ranged from 0 to 9 with the overall score categorised as follows: 7 to 9: “low risk of bias”,
4 to 6: “moderate risk”, and 0 to 3: “high risk” (S2 Table). For each included study, we also esti-
mated the precision (C) or margin of error, considering the sample size (SS) and the observed
prevalence (p) of MS from the formula SS = Z2p(1-p)/C2 where Z was the z-value fixed at
1.96 across studies (corresponding to 95% confidence interval). The desirable margin of error
was 5% (0.05) or lower.
Data extraction
Relevant data for this review were extracted using a purposeful design and a piloted extraction
form. The information extracted included 1) Author details [names and year of publication];
2) Study characteristics [country, study design, setting, data source, sampling method, sample
size, data collection period, response rate]; 3) Participants’ characteristics [age, gender, lifestyle
habits (smoking, alcohol misuse), HIV-related factors [time since diagnosis, severity of the dis-
ease, ART regimens and duration of treatment]; and 4) MS characteristics [diagnostic criteria
used, prevalence, number of participants tested and diagnosed with MS overall and by sub-
groups of interest].
Data synthesis and analysis
For each included study, the unadjusted prevalence of MS was estimated (number with MS/
total number of participants tested) overall and across major subgroups of interest. We used
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Fig 1. Flow diagram for the selection of studies.
doi:10.1371/journal.pone.0150970.g001
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DerSimonian-Laird random effects models to combine estimates from different studies to gen-
erate the overall prevalence of MS according to each diagnostic criteria. The random effects
model was chosen over the fixed effects in anticipation of substantial variations in MS preva-
lence estimates across the included studies. To minimise the effect of extreme prevalence on
the overall estimates, we first stabilised the variance of the raw prevalence with a single arcsine
transformation before pooling the data [9].
To account for the small number of studies that applied some definition criteria, and also to
account for similarities between some criteria, a decision was made to group together studies
that applied the Adult Treatment Panel III (ATPIII)-2004 and ATPIII-2005 criteria into the
ATPIII-2004-2005 group. Furthermore, studies that applied variants of the same criteria (e.g.
through the substitution of variables) were assessed together with studies that applied the origi-
nal criteria.
We assessed the heterogeneity between studies using the Cochran’s Q, I2 and H statistics
[10]. Noteworthy is that statistical approaches to assess heterogeneity can yield spurious results
within uncontrolled studies [11]. We explored the sources of heterogeneity by comparing the
prevalence of MS between subgroups defined by naturally occurring categories (e.g. gender and
geographic regions), or by using median values of the summary estimates of the continuous
characteristics (e.g. age, ART duration) across all eligible studies. Subgroups comparisons then
used the Q-test based on the Analysis of the Variance (ANOVA). Publication bias was assessed
using the funnel plots supplemented by formal statistical assessments using the Egger test of
bias [12]. All analyses were performed using the R programme (version 3.0.3 [2014-03-06])
and “meta” package.
The following sections report the findings of the systematic review and meta-analyses. The
data are presented by the overall MS prevalence as well as by subgroups of age, gender, HIV-
related factors, study location, publication year, sample size, and smoking status. Within each
subgroup, MS prevalence is presented by the definition criteria used.
Results
The review process
The process for selecting the relevant studies is summarised in Fig 1. In total, 1280 records
were identified via database searches. After removing all duplicates, we scanned the titles and
abstracts of 888 articles, of which 78 articles were further reviewed via full-texts. Of these, 59
articles met the inclusion criteria and were selected for this review. One article reported surveys
conducted in seven South American countries, leading to a total of 65 studies in the main
analyses.
Methodological quality of included studies
In all, 18 studies were categorised as having a low risk of bias while the remainder had a moder-
ate risk of bias. However, 37 studies did not indicate how participants were selected; seven
studies reported some form of random selection whereas 21 studies indicated a non-random
sampling technique. A total of 25 studies reported the response rates which ranged from 31.2%
to 100% (median 88%).
Characteristics of included studies
The characteristics of the included studies are summarised in Table 1. Studies from all conti-
nents were represented as follows: Europe: 23, the Americas: 26, Africa: nine and Asia: four,
while three studies were intercontinental. Of the 65 included studies, 33 were localised studies,
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mainly conducted in urban settings, while the rest had national coverage. With regards to the
actual study sites, the majority (58) were solely hospital- or clinic-based, four were commu-
nity-based and three studies involved both locales. While about half of the studies (34) col-
lected data before or during 2007, only one-fifth (12 studies) were published in the same
period.
The studies consisted of 39 to 23853 participants with men comprising 19–95% (median
70.7%) of the samples [13,14]. The median age of participants was 41 years (range 17–73 years).
Smoking prevalence, reported in 47 studies, was 0–84% (median 39.8%) [15,16]. In the 37 studies
with data on CD4 cell count, levels ranged from 105 cells/μL (Benin) [17] to 535 cells/μL (USA)
[18] (median 394 cells/μL). The timespan of diagnosed HIV infection, reported in 20 studies, was
19.3 to 224.4 months [15,18] (median 67.6 months) while the duration of ART, described in 21
studies, was 14.6–78 months [17,19], (median 27 months). In the 28 studies that reported on
ART usage, 45–94% of the HIV-infected participants, were on ART [20,21] (median 76.2%). Of
those on ART, 17.3–61.5% (median 37.4%) were on protease inhibitors (PIs) [22,23], 19.4%
(median 43.4%) on non-nucleoside reverse transcriptase inhibitors (NNRTIs) [22,24], and 1.5–
85.5% (median 77.0%) on nucleoside reverse transcriptase inhibitors (NRTIs) [21,25]. Very few
studies provided information on the stage of the disease (S4 Table).
The included studies applied various international criteria to diagnose MS (S5 Table). Fifty-
one studies applied a single set of criteria; the most frequently used was the ATPIII-2001 in 30
studies followed by the ATPIII-2004-2005 (14 studies). The International Diabetes Federation
(IDF)-2005, Joint Interim Statement (JIS)-2009 and modified ATPIII-2005 criteria were used in
2 studies each while the European Group for the Study of Insulin Resistance (EGIR)-2003 in one
only. Of the 14 studies that compared theMS prevalence using two or more criteria, the following
combinations were reported: two criteria: IDF-2005 + ATPIII-2001 (7 studies), and IDF-2005 +
ATPIII-2005 (4 studies), and three criteria (1 study each): IDF-2005 + ATPIII-2005 + JIS-2009;
IDF-2005 + ATPIII-2001 + EGIR-2003; IDF-2005 + ATPIII-2001 + EGIR-2003.
Overall prevalence of metabolic syndrome
The most commonly used criteria to determine MS prevalence, alone or in combination with
other criteria, were the ATPIII-2001 (Fig 2: 38 studies, n = 16984), IDF-2005 (Fig 3A: 16 stud-
ies, n = 8250) and ATPIII-2004-2005 definitions (Fig 3B: 20 studies, n = 11255). The overall
MS prevalence rates by these criteria were 16.7% (95%CI, 14.6–18.8; I2 = 92.1%, p-hetero-
geneity<0.001), 18.0% (95%CI: 14.0–22.4; I2 = 95.8%, p<0.001) and 24.6% (95%CI: 20.6–28.8;
I2 = 95.8%, p<0.001), respectively. The prevalence ranges were 7.2% [26] to 31% [27] (ATPIII
2001), 7.8% [28] to 43.2% [29] (IDF 2005) and 12.3% [22] to 52% [30] (ATPIII 2004–2005).
The highest overall MS prevalence was by the EGIR criteria (31.3%, 95%CI: 26.8–36.0; I2 =
9.8%, p = 0.300) used in two studies (n = 446) (S1 Fig). A similarly high prevalence by the JIS
criteria (29.6%, 95%CI: 22.9–36.8; I2 = 91%, p<0.001) was based on four studies (n = 2404) (S2
Fig). MS prevalence by the modified ATPIII 2005 criteria, obtained from two studies
(n = 23919), was also high at 27.9% (95%CI: 6.7–56.5; I2 = 95.8%, p<0.001) (S3 Fig). However,
there were relatively few studies that determined the MS by these three criteria. The margin of
error (precision) across studies ranged from 1% to 12%, with only 18 studies (28%) having a
margin of error>5% (Table 1).
With a wide range of 16.7% to 31.3%, the pooled prevalence of MS differed significantly by
the various diagnostic criteria (p<0.001). Unsurprisingly, however, MS prevalence by modified
criteria was similar to that of studies that used the related original definition (S5 Table). There
was insufficient evidence of publication bias (all p0.060 for the Egger test) except for studies
that used the ATPIII 2001 criteria (p-Egger test = 0.040; Fig 4)
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Prevalence of metabolic syndrome within and across subgroups
Some of the findings are presented in the accompanying tables and figures while other data such
as the prevalence of MS by age, intra-country location, duration of HIV infection, ART status,
treatment period and year of publication are reported in the supplementary tables and figures.
Age. Older (>median age 41 years) compared with younger participants (41years) had
higher MS prevalence (S6 Table): ATPIII-2001: 19.7% vs. 13.2%, p<0.001, ATIII 2004–2005:
26.6% vs. 21.5%, p = 0.479 and IDF-2005: 22.3% vs. 16.4%, p = 0.361. Substantial heterogeneity
was apparent within age-groups regardless of the criteria (all p-heterogeneity<0.001).
Gender. Thirty-two of the 65 studies presented the MS data by gender; of these a single
study was conducted in men only (Italy) [31] and two in women only (USA) [27,32]. The crite-
ria most commonly used was the ATPIII 2001 in 16 studies for men (n = 8269) and 17 studies
for women (n = 3971). This was followed by the ATPIII 2004–2005 (13 studies, men: n = 5742,
women: n = 4470) and IDF 2005 definitions (11 studies, men: n = 3556, women: n = 2293).
The MS prevalence in men and women was as follows: ATPIII 2001: 14.6% (95%CI: 11.5–18.1)
and 17.5% (95%CI: 14.0–21.2); ATPIII 2004–2005: 23.7% (95%CI: 19.0–28.7) and 26.7% (95%
CI: 20.8–33.0); and IDF 2005: 13.4% (95%CI: 8.7–18.9) and 23.2% (95%CI: 15.9–31.4); Fig 5
and S6 Table. MS prevalence by the various criteria was significantly different in men
(p = 0.001) but not in women (p = 0.118). Heterogeneity presented within gender-groups
across criteria (all p-heterogeneity<0.001).
HIV-related factors
Duration of diagnosed HIV infection: The prevalence of MS, categorised by the duration of
diagnosed HIV infection (median cut-off point 68 months), differed across MS criteria (S6
Table). By the ATPIII-2001 definition, MS prevalence was significantly higher (p = 0.044) in
participants with longer (20.6%, 95%CI: 13.8–28.4) compared to shorter duration of diagnosed
HIV-infection (13.2%, 95%CI: 11.2–15.4). However, by the ATPIII-2004-2005, MS prevalence
was not significantly different: longer: 32.0% vs. shorter: 19.1%, p = 0.251. There was substan-
tial heterogeneity across and within criteria for MS prevalence by the duration of diagnosed
HIV infection; all p-heterogeneity<0.030 for within criteria except for studies below the median
duration which used the ATPIII-2001 criteria (p-heterogeneity = 0.581)
CD4 counts: Using a median cut-off point of 394 cells/μL, MS prevalence in participants
with high CD4 counts was significantly lower than in those with low CD4 counts by the IDF
2005 criteria: 10.4% (8.2–12.9) vs. 17.5% (14.4–20.8), p<0.001 (S6 Table). However, there was
little difference in MS prevalence by CD4 count levels using the ATPIII-2001 (17.4% vs. 15.6%,
p = 0.514) and ATPIII-2004-2005 definitions (24.6% vs. 26.5%, p = 0.747). The prevalence
across MS diagnostic criteria was significantly different by CD4 count levels (all p0.020). Sub-
stantial heterogeneity was noted in MS prevalence by CD4 count levels within studies that
applied the ATPIII-2001 and ATPIII-2004-2005 criteria (all p-heterogeneity0.035) but not
within studies that used the IDF-2005 definition (p-heterogeneity0.272).
Exposure to antiretroviral therapy: In studies that included treatment status (S6 Table), the
most commonly used MS criteria was the ATPIII 2001 (ART-exposed: 20 studies, n = 12148,
ART-naïve: 17 studies, n = 2659). MS prevalence, at 18.4% (95% CI: 15.9–21.1) in the ART-
exposed, was significantly higher (p = 0.001) than in the ART-naïve (11.8%, 95%CI: 9.3–14.7)
Fig 2. Overall metabolic syndrome prevalence in the HIV-infected: Adult Treatment Panel III (ATPIII) 2001 criteria. For each study the black
box represents the study estimate (prevalence of metabolic syndrome [MS]) and the horizontal bar about the 95% confidence intervals (95%CI). The size of
the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The
proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and measures of
heterogeneity. The dotted vertical line is centred on the pooled estimates.
doi:10.1371/journal.pone.0150970.g002
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(Fig 6). MS prevalence by the IDF 2005 criteria was also higher in the ART-exposed (19.6%,
95%CI: 14.2–25.6) compared to the ART-naïve (14.9%, 95%CI: 8.6–22.6) but this difference
was not significant; prevalence was similar by the ATPIII 2004–2005 definition (21.6%, 95%CI:
13.5–31.0 vs. 19.9%, 95%CI: 18.3–21.5). Interestingly, MS prevalence by the various criteria
was similar in the ART-exposed (p = 0.730) but significantly different in the ART-naïve
(p<0.001). Excluding the non-ART studies based on the ATPIII-2004-2005 where homogene-
ity was found (p-heterogeneity = 0.398), there was significant heterogeneity within ART-
exposed and ART-naïve groups (all p-heterogeneity<0.001).
Proportions of ART users and duration of ART treatment: MS prevalence by a high or low
proportion of ART users (median cut-off point 76.2%) was not significantly different within
criteria: ATPIII 2001: 15.8% vs. 19.1%, p = 0.172; ATPIII 2004–2005: 38.3% vs. 23.8%,
p = 0.256; IDF 2005: 14.4% vs. 19.4%, p = 0.176. Using a cut-off point of 27 months for the
median length of ART use, MS prevalence was not significantly different for a longer or shorter
treatment duration within MS criteria: ATPIII 2001: 17.1% vs. 15.6%, p = 0.649; ATPIII 2004–
2005: 25.6% vs. 14.2%, p = 0.192; IDF 2005: 14.6% vs. 13.4%, p = 0.811. The prevalence within
the two sub-groups was similar across MS criteria (all p0.111). Substantial heterogeneity was
noted within all the above subgroups (all p-heterogeneity<0.001).
ART regimen: The median proportion of participants using PIs across the included studies
was 37.4% (S6 Table). Using this cut-off point, the pooled MS prevalence in studies with more
compared to fewer PI users by the IDF 2005 criteria was 18.5% (95%CI: 12.3–25.6) from six
studies (n = 4927) versus 10.0% (95%CI: 7.2–13.4) (p = 0.016) in a single study (n = 400). How-
ever, the MS prevalence by proportion of PI users was not significantly different by the ATPIII
2001 (17.7% vs. 19.3%, p = 0.593) and ATPIII 2004–2005 definitions (25.8% vs. 30.4%,
p = 0.517). MS prevalence, determined by the various criteria, differed across studies of PI
users (p = 0.022) and in those with fewer median participants on PIs (p = 0.001).
The median proportion of participants using NNRTIs was 43.4%, the cut-off value used to
determine a high and low proportion of users. The pooled MS prevalence in studies with more
compared to fewer NNRTI users was 17.2% (95%CI: 9.5–26.6) versus 33.8% (95%CI: 23.4–45.1)
(p = 0.020) by the ATPIII 2004–2005 criteria. MS prevalence according to NNRTI regimen status
was not significantly different by the ATPIII 2001 (19.5% vs. 15.1%, p = 0.221) and IDF 2005 cri-
teria (10.5% vs. 19.8%, p = 0.058). However, MS prevalence within the two NNRTI subcategories
was significantly different by the various MS criteria (all p0.007), (S6 Table).
In studies with a high proportion of participants on NRTI (median>77.0%), the pooled
prevalence by the ATPIII 2001 criteria was 17.9% (95%CI: 9.4–28.7) compared to 22.8% (95%
CI: 14.3–32.7) in studies with fewer participants on NRTIs (p = 0.474) (S6 Table). There was
insufficient data by the IDF 2005 and ATPIII 2004–2005 criteria for analysis.
Study location
Intercontinental: The ATPIII 2004–2005 MS criteria was the only one commonly used by stud-
ies across continents. The pooled MS prevalence by this criteria was the highest in the Americas
Fig 3. Overall metabolic syndrome prevalence in the HIV-infected. Figure panels are for the prevalence
of metabolic syndrome according to the International Diabetes Federation 2005 criteria (panel a), and
according to the Adult Treatment Panel III 2005 criteria overall and by continent (panel b). For each study the
black box represents the study estimate (prevalence of metabolic syndrome [MS]) and the horizontal bar
about the 95% confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance.
The diamond at the lower tail of the figure is for the pooled effect estimates from random effects models. The
proportional contribution of each study (weight) to the pooled estimates is also shown, together with the
prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled
estimates.
doi:10.1371/journal.pone.0150970.g003
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Fig 4. Funnel plots for included studies across different diagnostic criteria for metabolic syndrome.
For each diagnostic criteria, the arcsine transformed proportion of participants with metabolic syndrome
(relative to the total sample) for each relevant study (horizontal axis) is plotted against its standard error
(vertical axis), and represented by the dots. When the dots distribute symmetrically in a funnel shape, this
implies an absence of bias. A p-value <0.05 (Egger test) indicates significant publication bias.
doi:10.1371/journal.pone.0150970.g004
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Fig 5. Pooledmetabolic syndrome prevalence in the HIV-infected presented by gender: International Diabetes Federation 2005 criteria. For each
study the black box represents the study estimate (prevalence of metabolic syndrome [MS]) and the horizontal bar about the 95% confidence intervals (95%
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(9 studies, n = 7450) at 27.3% (95%CI: 21.7–33.4; I2 = 96.6%, p<0.001). This was followed by
Europe (5 studies, n = 1571) and Asia (4 studies, n = 1521) where the prevalence was similar.
At 24.1% (95%CI: 11.2–40.1; I2 = 97.7%, p<0.001) in Europe and 24.1% (95%CI: 21.6–26.8; I2
= 16.8%, p = 0.307) in Asia, MS prevalence on these continents were almost as high as in the
Americas. MS prevalence in Africa (2 studies, n = 713), however, was much lower at 16.4%
(95%CI: 8.7–25.9; I2 = 90%, p = 0.002), (Fig 3B and S6 Table). The differences in prevalence
across continents was not statistically significant (p = 0.284).
Intra-country: MS prevalence was similar across regional studies compared with the corre-
sponding national data (ATPIII 2001: 16.0% vs. 17.1%, p = 0.607; ATPIII 2004–2005: 24.3% vs.
25.4%, p = 0.861; IDF 2005: 17.4% vs. 18.7%, p = 0.785) (S6 Table). According to the criteria
used, the prevalence of MS within a country differed in regional studies (p = 0.024) but was not
significantly different in national studies (p = 0.109).
Year of publication
The prevalence of MS in studies reported before, compared to after, 2010 was significantly
higher by the ATPIII 2004–2005 criteria (30.6% vs. 21.5%, p = 0.012) but not by the other defi-
nitions (all p0.100). However, MS prevalence in the earlier publications differed significantly
by criteria (16.4% vs. 30.6% vs. 14.5% for ATPIII-2001, ATPIII-2004-2005, IDF-2005 respec-
tively, p<0.001).
Sample size and smoking status
The median number of participants per study was 292 with this sample size used to classify
studies as either large or small. MS prevalence was similar in large and small studies within cri-
teria: ATPIII 2001:18.3% vs. 15.1%, p = 0.115; ATPIII 2004–2005: 24.7% vs. 25.6%, p = 0.989;
IDF 2005: 19.0% vs. 16.1%, p = 0.388. There was no significant difference in prevalence by sam-
ple size category across MS criteria (all p0.059).
Smoking status
The absence of a significant difference in the prevalence of MS in studies with a high or low
proportion of smokers (median 39.8%) within criteria is demonstrated in S6 Table. The preva-
lence was as follows: ATPIII 2001: 14.8% vs. 17.6%, p = 0.234; ATPIII 2004–2005: 28.8% vs.
22.2%, p = 0.193; IDF 2005: 18.4% vs. 14.6%, p = 0.565. However, MS prevalence varied signifi-
cantly across criteria in studies with a higher proportion of smokers (p = 0.010). There was sub-
stantial heterogeneity within all the above subgroups (all p-heterogeneity<0.001).
Discussion
Overview of MS prevalence
To our knowledge, this is the first comprehensive review and meta-analysis of the MS preva-
lence in the global HIV-infected population. Among the key findings was the high burden of
MS in the HIV-infected population; 16.7–31.3% of HIV-infected adults had MS by the various
definitions. The wide prevalence range is indicative of substantial heterogeneities across and
within the diagnostic criteria. Two different criteria, the ATPIII-2001 and the EGIR-2003,
CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect estimates from random
effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the prevalence estimates and
measures of heterogeneity. The dotted vertical line is centred on the pooled estimates. Furthermore, pooled effect estimates are provided separately by
gender. The horizontal arrow head indicates that the representation of the effect estimates and 95% confidence intervals has been truncated.
doi:10.1371/journal.pone.0150970.g005
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Fig 6. Pooledmetabolic syndrome prevalence in the HIV-infected presented by antiretroviral therapy (ART) use: Adult Treatment Panel 2001
criteria. For each study the black box represents the study estimate (prevalence of metabolic syndrome [MS]) and the horizontal bar about the 95%
confidence intervals (95%CI). The size of the boxes is proportional to the inverse variance. The diamond at the lower tail of the figure is for the pooled effect
estimates from random effects models. The proportional contribution of each study (weight) to the pooled estimates is also shown, together with the
prevalence estimates and measures of heterogeneity. The dotted vertical line is centred on the pooled estimates. Furthermore, pooled effect estimates are
provided separately by ART use. The horizontal arrow head indicates that the representation of the effect estimates and 95% confidence intervals has been
truncated.
doi:10.1371/journal.pone.0150970.g006
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reported the overall lowest and highest prevalences, respectively. Notably, the differences in
prevalences were not fully explained by the major study characteristics. For example, variations
in MS prevalence were also apparent within subgroups such as in younger participants, men,
the Americas, regional studies, older publications and smokers.
Notably, the MS prevalence in the HIV-infected is within the range of the 17–46% reported
in the general population. This highlights that the risk for developing MS in HIV-infected indi-
viduals is likely comparable to that in the general population. It also underscores the impor-
tance of traditional cardio-metabolic risk factors in the former; these are likely to exert an
equal influence on HIV-infected individuals as they do in the general population. The wide
range in MS prevalence in the general population mimics that found in this review and is possi-
bly due to similar reasons discussed above [33–35].
The similar exposure to cardio-metabolic risk factors in the HIV-infected compared to the
general population is likely attributable to the introduction of ART which has dramatically
reduced HIV-related morbidity and mortality. ART has prolonged lifespans and subsequently
enabled the HIV-infected to be exposed to the same risk factors and diseases as the general
population. Reinforcing the likelihood of similar pathways in the development of MS in the
HIV-infected and general populations was the higher MS prevalence in older compared to
younger HIV-infected individuals, which is mirrored in general populations [33].
The higher MS prevalence in women compared to men in this analysis has also been shown
in general populations but reports diverge in the latter [33–35]. Further research may be
required to understand the differences in MS prevalence by gender which is usually driven by
higher rates of obesity [36]. There may also be HIV specific factors that contribute to greater
cardio-metabolic abnormalities in women compared to men that require further investigation.
MS prevalence by diagnostic criteria
Across the three major criteria (ATPIII 2001, ATPIII 2004–2005, and IDF 2005) used by most
studies in this review, the estimated MS prevalence was highest by the ATPIII 2004–2005 defi-
nition (24.6%). This was not unexpected because the threshold for hyperglycaemia in the
ATPIII 2004–2005 is lower than that for the ATPIII 2001criteria; this leads to more individuals
diagnosed with MS by the former classification. Furthermore, the inclusion of lipid-lowering
and/or antihypertensive medications in the ATPIII 2004–2005 definition also contributes to a
higher MS diagnosis compared with the ATPIII 2001. In contrast, the compulsory incorpo-
ration of waist circumference in the IDF 2005 criteria excludes many HIV-infected participants
with abnormal biochemical parameters but normal waist circumference from the diagnosis.
This is of particular relevance and frequently reported in HIV studies [25,37–41].
Not surprisingly, few studies that used more than one definition to diagnose MS applied the
same combination of criteria [25,42]. In this review, direct comparison of MS prevalence by
the various criteria is not meaningful because there was substantial overlap of the confidence
intervals around the prevalence estimates. Also, only few studies used multiple diagnostic crite-
ria which would limit the value of such an analysis.
HIV-related influences on MS prevalence
Although HIV specific characteristics were associated with the prevalence of MS in the current
analyses, these need to be interpreted with care because of the inability to control for the many
confounding influences. Nonetheless, the association of MS prevalence with a greater duration
of diagnosed HIV infection accords with the influence of HIV infection on the development of
cardio-metabolic abnormalities. Then again, a longer interval since HIV diagnosis likely
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correlates with older age, which is a risk factor for MS in both the HIV-infected and general
populations. It may also possibly reflect the specific effects of prolonged ART.
The relation between CD4 count and MS was unclear with some studies reporting a direct
link [43,44] while others demonstrate the inverse [45] or no association [46,47]. However,
these findings were based on only seven studies and did not report the viral loads
[13,17,22,40,42,48,49]. Without such information it is difficult to draw conclusions on this
relationship. A high viral load has been associated with the development of MS, possibly con-
tributing to the high incidence of low high density lipoprotein cholesterol (HDL-C) levels and
high triglycerides in some studies [16,50].
The higher MS prevalence in ART-exposed compared to ART-naïve participants by the
ATPIII-2001 criteria was consistent with findings from prospective studies. One of these stud-
ies demonstrated an increase in MS prevalence from 16.6% to 25% with an incidence of 14/100
patients-year among participants initiated and maintained on the same HAART regimen for
48 weeks [51]. In another study, a large international, multicentre, randomised trial conducted
for three years after the initiation of ART, the incidence of MS was 12/100 patients-year and 8/
100 patients-year according to the ATPIII 2001 and the IDF 2005 criteria, respectively [28].
Also, the D:A:D study which followed HIV patients on ART over a long period, demonstrated
a substantial increase in MS prevalence [52].
ART regimen was significantly associated with MS with notable differential findings by the
class of drug used. The higher MS prevalence in studies with a greater compared to smaller pro-
portion of PI users accords with four trials where PI-based regimens were found to accelerate
progression to MS [37,38]. The initiation of ART leads to chronic inflammation and an incom-
pletely restored immune system. This may perhaps be the link between PI use and the develop-
ment of MS [53,54]. Furthermore, PI drugs have been reported to be associated with more
severe dyslipidaemia compared to NNRTI, which is a feature of metabolic syndrome. This
would explain at least in part the higher prevalence of MS in patients on PI. Patients on this
regimen thus need to be closely monitored for the development of cardio-metabolic abnormali-
ties. Moreover, once such abnormalities arise, it is important to review ART management and
change to metabolically neutral regimens.
An alternative ART regimen to PIs in patients with MS may be NNRTIs because a lower MS
prevalence, by some criteria, was detected in studies with a high compared to low proportion
of participants on these drugs. Although our analyses were based on only seven studies
[14,20,22,29,37,41,44] this suggests that, unlike PIs, NNRTIs do not adversely influence cardio-
metabolic function and may possibly even have a beneficial impact. Indeed, a randomised con-
trolled study reported improvements in cardio-metabolic profiles with increases in HDL-C lev-
els in patients on nevirapine and nelfinavir [55]. On the other hand, several prospective trials
have found no association between the use of NNRTIs and MS [37,38]. Further research is
required to clearly describe the relationship between NNRTIs and cardio-metabolic function-
ing, particularly since there is a dearth of data on the influence of this class of ART on MS.
Other influences on MS prevalence
Although there was no difference in MS prevalence between studies with a high and low propor-
tion of smokers, conclusions on the absence of an association should be cautioned against. The
studies analysed included only current smokers with no consideration given to recent smoking
cessation or ex-smokers. Reports describe the duration of smoking cessation to be inversely
related to future cardiovascular disease risk to a moderate degree. Furthermore, aspects not con-
sidered in this review such as the smoking interval and the quantity smoked have been strongly
correlated with the development of MS and atherosclerosis progression [56–58].
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The lower MS prevalence by the ATPIII 2004–2005 criteria in recent compared to older
publications was surprising. We expected the trend to mimic that of the general population
with a rise in MS prevalence in the HIV-infected over time. Moreover, with the introduction
and widespread uptake of ART leading to longevity, we anticipated the subsequent develop-
ment of MS with age, which would be reported in recent publications. Nevertheless, our find-
ings are elucidated by the differences in participant characteristics between the two publication
periods. Participants in publications prior to 2010 were older and included more women who
were shown to have a higher MS prevalence than men in this review.
Despite an unbalanced representation of studies worldwide, the prevalence of MS was essen-
tially similar within and across the major regions including by continent and intra-country
site, regardless of the definition criteria used. The absence of studies conducted specifically in
rural settings with a likely lower MS prevalence than in urban centres, particularly in develop-
ing regions, may account for this finding. Alternatively, it may perhaps reflect the ubiquitous
worldwide influence of globalisation and highlight the likelihood of similar influences on the
development of MS in the HIV-infected population globally. Thus, broad-based general strate-
gies may perhaps be devised to address the MS burden in all HIV-infected populations.
Strengths and limitations
Strengths. We searched multiple databases extensively, applying reproducible criteria to
capture the most number of studies on MS prevalence worldwide. This allowed us to provide a
comprehensive global perspective on the emerging burden of adverse cardio-metabolic profiles
in the HIV-infected population. Furthermore, we used robust approaches to pool studies while
minimising the effects of extreme studies. We also used a detailed approach to investigate the
potential sources of heterogeneity. Our post-hoc power estimation revealed that over two-
thirds of the included studies were adequately powered to provide precise estimates of the MS
prevalence in the overall sample. This has likely translated into stable and robust pooled esti-
mates by combining those primary studies.
Limitations. Our findings may not be generalizable to all HIV-infected individuals
because most of the studies were conducted in non-randomly selected populations. The wide
range in MS prevalence, because of the different criteria used across studies, although expected,
made estimations of the actual burden difficult. Nevertheless, apart from differences in the cri-
teria themselves that contributed to this wide range, other factors were also likely responsible.
For example, MS prevalence would be expected to differ across time, particularly in the HIV-
infected as access to care expanded, the uptake of ART increased and the effectiveness of ther-
apy improved with the introduction of HAART. In some included studies, participants were
selected with consideration to histories of existing CVD risk factors, which in turn can result in
MS prevalence rates different from those in a broader population of HIV-infected individuals.
This could possibly contribute to some of the heterogeneities observed across studies.
The infrequent reporting of the HIV specific markers of CD4 count and viral load precluded
in-depth analyses of their effects on MS. Similarly, data were missing on key study characteris-
tics which could be used in advanced analyses via meta-regressions. Furthermore, the inconsis-
tent number of studies across subgroups precluded meta-regression analyses to investigate the
possible contribution of each factor to MS prevalence. However, such comparisons would pos-
sibly have been biased by differences in study design and objectives, data collection techniques,
laboratory facilities and participant characteristics, and could not have been fully accounted for
in our meta-analyses. Especially difficult to control for would be HIV related characteristics
such as differences in disease stage, fat distribution including lipodystrophy, obesity and co-
existent infections such as hepatitis C and hepatitis B [59].
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Conclusion and Implications
The MS prevalence in HIV-infected individuals worldwide appears to be similar to that found
in the general population, suggesting similarities in the drivers of the syndrome, independent
of HIV status. Indeed, despite suggestions of significant signals, the inconsistent association of
HIV specific features including treatments with MS prevalence suggest that their contribution,
if any, is of a lesser magnitude. Comparable with general populations, traditional risk factors
are likely the major contributors to the burden of cardio-metabolic abnormalities and MS in
HIV-infected individuals. Therefore, management strategies implemented in the general popu-
lation for these conditions, will likely reap similar benefits in the HIV-infected. Nevertheless,
the major challenge lies in devising and strengthening approaches to maximise cardio-meta-
bolic care while simultaneously ensuring optimal HIV management.
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